Product
Trabectedin
Aliases
trabectedin, Yondelis
Name
trabectedin
Target
PD-1 inhibitor
FDA Approved
No
Ema approved
Status
0
5 clinical trials
1 drug
1 abstract
5 indications
Indication
Soft Tissue SarcomaIndication
Dedifferentiated LiposarcomaIndication
Advanced Soft Tissue SarcomaIndication
High-risk Soft Tissue SarcomasIndication
SarcomaDrug
TrabectedinClinical trial
A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)Status: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated LiposarcomaStatus: Terminated, Estimated PCD: 2023-10-01
Abstract
Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).Org: Helios Klinikum Berlin-Buch, Charité–Universitätsmedizin Berlin, Medizinische Fakultät “Carl Gustav Carus“ der TU Dresden, Universitätsklinikum Würzburg, Universität Heidelberg,
Clinical trial
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
The TNT Protocol: A Phase 2 Study Using Talimogene Laherparepvec,Nivolumab and Trabectedin as First, Second/Third Line Therapy for Advanced Sarcoma, Including Desmoid Tumor and ChordomaStatus: Recruiting, Estimated PCD: 2024-12-31